Insulin use in Type 2 diabetic patients: a predictive of mortality in covid‑19 infection

Abstract

Introduction Starting December 2019, the world has been devastated by the rapid spread of coronavirus disease 2019 (Covid-19). Many risk factors have been associated with worse outcomes and death from Covid-19 pneumonia including having diabetes mellitus. To date, it is not clear if all group of diabetics share the same risk of complications with COVID-19 infection. This study aims to compare disease severity and mortality rate in insulin users versus non-insulin users. Methods In this retrospective case–control study conducted at the largest health care network in New York state, we included adult, diabetic patients admitted from March 2020 to October 2020 with Covid-19 pneumonia. We compared the baseline characteristics in addition to outcomes of diabetic patients on home insulin (cases) and non-insulin user diabetics (controls). In addition, to determine if home insulin use is associated with an increased mortality, we conducted a cox regression analysis. Results We included 696 patients in the study period with a median age of 57 years, interquartile range [IQR] 51–62, and median body mass index 29.9 (IQR: 26–34.7). The majority (476 [68%]) were males. We identified 227 cases (33%) and 469 controls (67%). More cases than controls were hypertensive (74% vs 67%, p = 0.03), on ACE/ARB (50% vs 42%, p = 0.05), and had a hemoglobin A1c > 8.1 (71% vs 44%, p < 0.001). More cases had AKI (52% vs 38%, p < 0.001), however no significant differences were found in intubation rates (26% vs 24%, p = 0.54), detection of pulmonary embolism (4% vs 6%, p = 0.19) or death rate (15% vs 11%, p = 0.22) comparing cases and controls. In a multivariate analysis, we found that home insulin use was independently associated with increased risk of death: Hazard ratio: 1.92, 95% confidence interval (1.13–3.23). Conclusion We showed herein that diabetic patients on home insulin with COVID-19 pneumonia, have worse outcomes and increased mortality compared to diabetics on oral antihyperglycemic agents. Close monitoring of insulin-dependent type II diabetic patients is needed in the current pandemic.

Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis

“…Finally, 169 publications were included, of which 147 were new publications (Fig. 1) [3][4][5][6][7][8][9][10]. We conducted 177 meta-analyses (83 on COVID-19-related death and 94 on COVID-19 severity), compared with 77 meta-analyses in our original systematic review and metaanalysis [1].…”

Comorbidities in the COVID-19 Pandemic: Scopus-Based Bibliometric Analysis

“… 17 18 Overall, insulin-dependent conditions increase the risk of COVID-19 pneumonia compared to conditions treatable with oral antidiabetic agents. 19 …”

The Implications of the Pandemic with Covid-19 in the Glycemic Control of People with Type 2 Diabetes

“…29 Some studies have reported that insulin use in patients with diabetes was associated with higher morbidity and mortality related to COVID-19. 30 Patients on insulin therapy are more likely to have more severe diabetes and more extended hospital stays. 31 In addition, glucose dysregulation and increasing insulin use are associated with a more severe form of COVID-19.…”